SL
ADMA icon

Salomon & Ludwin’s ADMA Biologics ADMA Stock Holding History

Salomon & Ludwin’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20.1K Sell
2,332
-736
-24% -$6.71K ﹤0.01% 1139
2026
Q1 		$28.2K Buy
3,068
+1,360
+80% +$21.5K ﹤0.01% 824
2025
Q4 		$30.8K Buy
1,708
+28
+2% +$472 ﹤0.01% 599
2025
Q3 		$24.6K Buy
+1,680
New +$28.8K ﹤0.01% 686

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Salomon & Ludwin's ADMA Position: Q2 2026 in Review

Salomon & Ludwin reduced its ADMA Biologics (ADMA) stake by 24% in Q2 2026, selling an estimated $6.71K and leaving 2,332 shares worth $20.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1139.

Salomon & Ludwin first reported a position in ADMA in Q3 2025 and has held it in 4 quarters since. The position peaked at $30.8K in Q4 2025. 322 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • Salomon & Ludwin held 2,332 shares of ADMA Biologics worth $20.1K as of Q2 2026.
  • Salomon & Ludwin sold 736 ADMA Biologics shares in Q2 2026, an estimated $6.71K.
  • ADMA Biologics made up ﹤0.01% of Salomon & Ludwin's portfolio in Q2 2026, its #1139 holding.
  • Salomon & Ludwin first reported a position in ADMA Biologics in Q3 2025 and has held it in 4 quarters since.
  • Salomon & Ludwin's ADMA Biologics position peaked at $30.8K in Q4 2025.
  • 322 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Salomon & Ludwin's 13F filing for Q2 2026, filed 7 Aug 2026.